Roivant Sciences (ROIV) Net Margin Growth (3y) (2023 - 2026)
Powered by 
Analysis
Roivant Sciences (ROIV) Net Margin Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.30 Bn | 197.31 Bn | 7.24 Bn | 388.00 |
| 2 | Gilead Sciences | 181.15 Bn | 177.98 Bn | 6.22 Bn | -15,026.00 |
| 3 | Vertex Pharmaceuticals | 132.07 Bn | 124.21 Bn | 2.84 Bn | -374.00 |
| 4 | Regeneron Pharmaceuticals | 82.84 Bn | 74.85 Bn | 3.93 Bn | -44.00 |
| 5 | Argenx Se | 61.60 Bn | 56.42 Bn | 1.37 Bn | 6,620.00 |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | -13,815.00 |
| 7 | Alnylam Pharmaceuticals | 34.25 Bn | 30.94 Bn | 992.69 Mn | 9,934.00 |
| 8 | Biogen | 31.24 Bn | 29.95 Bn | 1.96 Bn | -2,059.00 |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | -1.86 Mn |
| 10 | Insmed | 28.11 Bn | 26.95 Bn | 358.27 Mn | 31,387.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.86 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Sep 30, 2025 | -804,829.00 |
| Jun 30, 2025 | -443,129.00 |
| Dec 31, 2024 | 100,240.00 |
| Sep 30, 2024 | -464,207.00 |
| Jun 30, 2024 | 202,629.00 |
| Dec 31, 2023 | 2.55 Mn |
| Sep 30, 2023 | -503,301.00 |
| Jun 30, 2023 | -100,996.00 |